Erworbene Faktor-V-Inhibitoren

Zusammenfassung

Erworbene Faktor-V-Inhibitoren sind eine seltene Gerinnungsstörung. Weltweit wurden bisher 72 Fälle publiziert. Die Inzidenz scheint jedoch zuzunehmen, was wahrscheinlich auf den gehäuften Einsatz von Fibrinklebern zurückzuführen ist. Diese Metaanalyse untersucht die prädiponierenden Faktoren, die Pathogenese, diagnostische Methoden, klinisches Erscheinungsbild, therapeutische Möglichkeiten und den langfristigen Verlauf aller bisher publizierten Fälle von Faktor-V-Inhibitoren.

Schlüsselwörter

Faktor-V-Inhibitoren - erworbene Gerinnungsstörungen

• LITERATUR

• 1 Abe T, Kazama M, Itokazu K. et al. A case of sigmoid cancer who acquired factor V inhibitor producibility and treated with factor VIII inhibitor bypassing activity preparation FEIBA - with bibliographic review. Rinsho Ketsueki 1980; 21: 1664-73
• 2 Ballester OF, Morelli G, Saba H. l, Foulis P. An IgG, time dependent, acquired factor V (FV) inhibitor. Blood 1990; 76: 411a
• 3 Berruyer M, Amiral J, Ffrench P. et al. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors. J Thorac Cardiovasc Surg 1993; 105: 892-7
• 4 Blecker SM, Williams AC. Postextraction bleeding in a patient with an acquired circulating anticoagulant against factor V. Oral Surg 1971; 32: 538-42
• 5 Brandt JT, Britton A, Kraut E. A spontaneous factor V inhibitor with unexpected laboratory features. Arch Pathol Lab Med 1986; 110: 224-7
• 6 Bryning K, Leslie J. Factor V inhibitor and bullous pemphigoid. Br Med J 1977; 2: 677-8
• 7 Buclin T, Schmidt PM, Hauert J. et al. Inhibiteur acquis du facteur V traité par immuno-globulines intraveineuses. Schweiz Med Wochenschr 1992; 122: 1968-70
• 8 Chediak J, Ashenhurst JB, Garlick I, Desser RK. Successful managment of bleeding in a patient with factor V inhibitor by platelet transfusion. Blood 1980; 56: 835-41
• 9 Chiu HC, Koneti Rao A, Beckett C, Colman RW. Immune complexes containing factor V in a patient with an acquired neutralizing antibody. Blood 1985; 65: 810-8
• 10 Cmolik BL, Spero JA, Magovern GJ, Clark RE. Redo cardiac surgery: late bleeding complications from topical thrombin-indu-ced factor V deficiency. J Thorac Cardiovasc Surg 1993; 105: 222-8
• 11 Chong LL, Wong YC. A case of factor V inhibitor. Am J Hematol 1985; 19: 395-9
• 12 Coots MC, Muhleman AF, Glueck H. l. Hemorrhagic death associated with a high titer factor V inhibitor. Am J Hematol 1978; 4: 193-206
• 13 Crowell EB. Observations of a factor V inhibitor. Br J Hematol 1975; 29: 397-404
• 14 Diem K, Mayr W, Sautner T. et al. Anti-HLA antibody removal by IgG immunoapheresis in highly sensitized renal transplant recipients. J Am Soc Nephrol 1995; 6: 1080a
• 15 DuMoulin A, Müller-Derlich J, Bieber F. et al. Antibody based immunoadsorption as a therapeutic means. Blood Purif 1993; 11: 145-9
• 16 Feinstein D. l. Acquired inhibitors of factor V. Thromb Haemost 1978; 39: 663-74
• 17 Feinstein D. l, Rapaport S. l, Chong MMY. Factor V inhibitor: report of a case, with comments on a possible effect of streptomycin. Ann Int Med 1973; 78: 385-8
• 18 Feinstein D. l, Rapaport S. l, McGehee WG, Patch MJ. Factor V anticoagulants: clinical, biochemical and immunological observations. J Clin Invest 1970; 49: 1578-88
• 19 Ferguson JH, Johnston CL, Howell DA. A circulating inhibitor (Anti-AcG) specific for the labile factor V of the blood clotting system. Blood 1958; 13: 382-97
• 20 Fratantoni JC, Hilgartner M, Nachman RL. Nature of the defect in congenital factor V deficiency. Study in a patient with an acquired circulating anticoagulant. Blood 1972; 39: 751-8
• 21 George S, Nagabhushana MS, Cyran EM. Coagulopathy due to an acquired factor V inhibitor and subsequently thrombosis. Am J Hematol 1995; 49: 98-100
• 22 Gordon B, Haire W, Duggan M. et al. Factor V inhibitor developing after liver transplantation in a 3-year-old child. Pediatrics 1991; 88: 156-9
• 23 Grace CS, Wolf P. A high titer circulating inhibitor of human factor V: clinical, biochemical and immunological features and its treatment by plasmapheresis. Thromb Diath Haemorrh 1975; 34: 322
• 24 Grigg AP, Dauer R, Thurlow PJ. Bleeding due to an acquired inhibitor of platelet associated factor V. Aust N Z J Med 1989; 19: 310-4
• 25 Handley DA, Duncan EM. A circulating anticoagulant specific for factor V. Pathology 1969; 1: 265-72
• 26 Hörder MH. Isolierter Faktor-V-Mangel bedingt durch einen spezifischen Hemmkörper. Acta Haematol 1955; 13: 235-7
• 27 Hörder MH, Sokal G. Inhibitorstudien bei familiärem Faktor-V-Mangel. Acta Haematol 1955; 14: 65-8
• 28 Hurtubise PE, Coots MC, Jacob DJ. et al. A monoclonal IgG4 (λ) with factor V inhibitory activity. J Immunol 1979; 122: 2119-21
• 29 Jobard J, Pourcher N, Gratecos N, Bayle J. Syndrome hemorrhagique du à un anticoagulant circulant antifacteur V. Presse Med 1983; 12: 1606
• 30 Kapur A, Kelsey PR, Isaaks PET. Factor V inhibitor in thrombosis. Am J Hematol 1993; 42: 384-8
• 31 Kaspar CK. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-72
• 32 Knöbl P, Derfler K, Korninger L. et al. Elimination of acquired factor VIII antibodies by extracorporal antibody-based immunoadsorption (Ig-Therasorb). Thromb Haemost 1995; 74: 1035-8
• 33 Koyama T, Saito T, Kusano T, Hirosawa S. Factor V inhibitor associated with Sjögren's syndrome. Br J Haematol 1995; 89: 893-6 24
• 34 Kuto M, Izuchi Y, Deguchi K. et al. An inhibitor against factor V occurring postoperatively in a case of pancreatic cancer. Acta Haematol Japon 1981; 44: 938-50
• 35 Lane TA, Shapiro SS, Burka ER. Factor V antibody and disseminated intravascular coagulation. Ann Int Med 1978; 89: 182-5
• 36 Lazarchick J, Wolff CM, Pepkowitz SH. et al. Factor V inhibitor associated with immune complex formation. Arch Pathol Lab Med 1986; 110: 448-51
• 37 Lerolle D, Dreyer-Dufer C, Allain JP. Anticoagulant circulant specifique du facteur V. Nouv Presse Med 1981; 10: 1483-7
• 38 Lopez VR, Pflugshaupt R, Bütler R. A specific inhibitor of human clotting factor V. Acta Haematol (Basel) 1968; 40: 275-85
• 39 Massignon D, Roullit S, Espinouse D, Coeur P. Apparition d'un anticoagulant circulant antifacteur V après intervention chirurgicale. Ann Fr Anesth Reanim 1989; 8: 70-2
• 40 Mazzucconi MG, Solinas S, Chistolini A. et al. Inhibitor of factor V in severe factor V congenital deficiency. A case report. Nouv Rev Fr Hematol 1985; 27: 303-5
• 41 Muntean W, Zenz W, Finding K. et al. Inhibitor to factor V after exposure to fibrin sealant during cardiac surgery in a two-year-old child. Acta Paediatr 1994; 83: 84-7
• 42 Nesheim ME, Nichols WL, Cole TL. et al. Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest 1986; 77: 405-15
• 43 Nichols WL, Daniels TM, Fisher PK. et al. Inhibitor of coagulation factor V and thrombin associated with surgical use of topical bovine thrombin or fibrin glue. Blood 1991; 78 (Suppl. 01) 63
• 44 Nilsson IM, Hedner U, Ekberg M, Denne-berg T. A circulating anticoagulant against factor V. Acta Med Scand 1974; 195: 72-9
• 45 Okajima A, Horii J, Nasu K. et al. Factor V inhibitor with double cancer. Rinsho Ketsueki 1989; 30: 514-9
• 46 Onoura CA, Lindenbaum J, Nosseel HL. Massive hemorrhage associated with circulating antibodies to factor V. Am J Med Sci 1973; 265: 407-17
• 47 Ortel TL, Quinn-Allen MA, Charles LA. et al. Characterisation of an acquired inhibitor to coagulation factor V. J Clin Invest 1992; 90: 2340-7
• 48 Rapaport S. l, Ziveln A, Minow RA. et al. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol 1992; 97: 84-91
• 49 Smid WM, de Wolf JTM, Nijland JH. et al. Severe bleeding caused by an inhibitor to coagulation factor V: a case report. Blood Coag Fibrinolys 1994; 5: 133-7
• 50 Spero JA. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases. J Neurosurg 1993; 78: 817-20
• 51 Stefanini M, Dameshek W. The Hemorrhagic Disorders: A Clinical and Therapeutical Approach. New York: Grund & Stratton 1955; 368
• 52 Stenbjerg S, Husted S, Myging K. A circulating factor V inhibitor: possible side effect of treatment with streptomycin. Scand J Hematol 1975; 14: 280-5
• 53 Stricker RB, Lane PK, Leffert JD. et al. Development of antithrombin antibodies following surgery in patients with prosthetic cardiac valves. Blood 1988; 1375-80
• 54 Taillan B, Fuzibet JG, Vinti H. et al. Factor V inhibitor in celiac disease. Am J Med 1989; 87: 360
• 55 Takase T, Fujimura Y, Mikami S. et al. Factor V inhibitor developing in a patient with pulmonary tuberculosis. Rinsho Ketsueki 1980; 21: 1038-46
• 56 Thomas F, Robert A, Luquel L. et al. Syndrome hemorragique mortel après mithramycine. La Presse Med 1989; 18: 182
• 57 Tribl B, Knöbl P, Derfler K. et al. Rapid elimination of a high titer spontaneous factor V antibody by extracorporal antibody-based immunoadsorption and immunosuppression. Ann Haematol 1995; 71: 199-203
• 58 Tsang PWK, Naiman SC. Development of antibodies to bovine thrombin and to other coagulation factors in three patients after cardiac surgery. Blood 1991; 78 (Suppl. 01) 65a
• 59 Vickars LM, Coupland RW, Naiman SC. The response of an acquired factor V inhibitor to activated factor IX concentrate. Transfusion 1985; 25: 51-3
• 60 Zehnder JL, Leung LLK. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990; 76: 2011-6